Stockscreener 앱 받기
6.22
4.36%
0.26
시간 외 거래:
6.22
Meiragtx Holdings Plc 주식(MGTX)의 최신 뉴스
Dynamic range: the key to MeiraGTx’s quest to control genes with pills - BioCentury
Duchenne Muscular Dystrophy Therapeutics Market Trends, Growth Insights, and Forecasts 2033 - WhaTech
Sanofi bets on Resalis’ oligonucleotide RES-010 for obesity - BioWorld Online
Gene Therapy Market Detailed Analysis and Forecast to 2031 - InsightAce Analytic
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress - The Manila Times
High Growth Tech Stocks to Watch in October 2024 - Simply Wall St
MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains? - MSN
(MGTX) Long Term Investment Analysis - Stock Traders Daily
Cell therapy weekly: US$225 million investment towards world-class research institute - RegMedNet
MeiraGTx’s Parkinson’s gene therapy shows promise in Phase I/II study - Clinical Trials Arena
MeiraGTx Holdings plc Inc. (MGTX) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study - Yahoo Finance
MeiraGTx Holdings Reports Promising Parkinson’s Therapy Results - Yahoo Finance
Items Tagged with 'glutamic acid decarboxylase' - BioWorld Online
Items Tagged with 'AAV-GAD' - BioWorld Online
Meiragtx looks to a phase III in Parkinson’s - BioWorld Online
Small Cap-MeiraGTx Reveals Encouraging Data From Parkinson's Study Showing Significant, Clinically Meaningful Changes in Key Efficacy Endpoints - AOL
MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings (NASDAQ:MGTX) - Seeking Alpha
MeiraGTx (MGTX) Sees Stock Surge After Clinical Results News - Stocks Telegraph
MeiraGTx stock gains on Parkinson’s drug data (NASDAQ:MGTX) - Seeking Alpha
Investors in MeiraGTx Holdings (NASDAQ:MGTX) from three years ago are still down 75%, even after 13% gain this past week - Simply Wall St
MeiraGTx reports positive Parkinson's gene therapy trial results By Investing.com - Investing.com UK
MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson's Disease - The Manila Times
MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease - StockTitan
Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data - Yahoo Finance
Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results - Benzinga
Piper Sandler maintains Overweight rating on MeiraGTx shares - Investing.com
Piper Sandler maintains Overweight rating on MeiraGTx shares By Investing.com - Investing.com South Africa
MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference - The Manila Times
MeiraGTx Holdings plc's (NASDAQ:MGTX) Profit Outlook - Yahoo Finance
DT Midstream (NYSE:DTM) Price Target Increased to $85.00 by Analysts at Barclays - Defense World
MeiraGTx's SWOT analysis: gene therapy firm's stock faces pivotal year By Investing.com - Investing.com South Africa
Harmony Biosciences (HRMY) Surges 6.7%: Is This an Indication of Further Gains? - Yahoo Finance
Bank of New York Mellon Corp Sells 14,485 Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) - Defense World
Beck Capital Management LLC Has $2.07 Million Stock Holdings in Martin Marietta Materials, Inc. (NYSE:MLM) - Defense World
Financial Metrics Check: Macrogenics Inc (MGNX)’s Ratios for Trailing Twelve Months - The Dwinnex
Leonardo Increases Stake In GEM Elettronica To 65% With EUR 16 Mln Investment - XM
MyCelx drops as revenue guidance pushed on order delay - Proactive Investors USA
Sei Investments Co. Decreases Stock Position in Martin Marietta Materials, Inc. (NYSE:MLM) - Defense World
Argent Trust Co Purchases New Stake in Globus Medical, Inc. (NYSE:GMED) - Defense World
MGO Global regains compliance with Nasdaq equity rule - Investing.com
Macrogenics Inc [MGNX] Records 200-Day SMA of $9.69 - Knox Daily
MeiraGTx (NASDAQ:MGTX) and LadRx (OTCMKTS:CYTR) Financial Contrast - Defense World
MGNX Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. (MGNX) Investors of Filing Deadline in Class Action Lawsuit - PR Newswire
The Gross Law Firm Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – MGNX - EIN News
Grinta completes full divestment of Moncler shares - XM
MyEG Rises 8.6 Pct In Early Trade - BERNAMA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Metagenomi, Inc.MGX - PR Newswire
Globus Medical director Ann D. Rhoads sells shares worth over $1 million - Investing.com
MacroGenics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsMGNX - Marketscreener.com
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
Understanding the Risks of Investing in MeiraGTx Holdings plc (MGTX) - Knox Daily
Is MeiraGTx Holdings plc (MGTX) The Best Rated Penny Stock To Buy According to Analysts? - MSN
10 Best Rated Penny Stocks To Buy According to Analysts - Insider Monkey
Investing in MeiraGTx Holdings plc (MGTX): What You Must Know - Knox Daily
Financial Survey: MeiraGTx (NASDAQ:MGTX) vs. Krystal Biotech (NASDAQ:KRYS) - Defense World
Public Equity Report: AnaptysBio, Avidity draw nine-digit offerings - BioCentury
MeiraGTx Holdings plc (NASDAQ:MGTX) Director Perceptive Advisors Llc Purchases 1,250,000 Shares of Stock - Defense World
MeiraGTx (NASDAQ:MGTX) Price Target Cut to $9.00 - Defense World
2.02%
0.47%
자본화:
|
볼륨(24시간):